title: Antiviral strategies: the present and beyond.
abstract: Historically, vaccine strategies have proven to be most effective at eradicating the targeted virus infections. With the advent of new or re-emerging altered viruses, some of which jump species to infect humans, the threat of viral pandemics exists. The protracted time to develop a vaccine during a pandemic necessitates using antiviral drugs in the intervening months prior to vaccine availability. Antiviral drugs that are pathogen specific, for example Amantidine, Tamiflu and Relenza, targeted against influenza viruses, are associated with the emergence of virus strains that are drug resistant. The use of ribavirin, a more broad spectrum antiviral, in combination therapies directed against influenza and hepatitis C virus, has proven effective, albeit to a modest extent. Attention is focused on the potential use of interferons (IFN)-alpha/beta as broad spectrum antivirals in acute infections, to invoke both direct antiviral effects against viruses and activation of specific immune effector cells.
authors.affiliation: Division of Cellular and Molecular Biology, Toronto General Research Institute, University Health Network, Toronto, Canada.
authors.forename: J D
authors.initials: JD
authors.lastname: Burke
authors.forename: E N
authors.initials: EN
authors.lastname: Fish
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy; D016898:Interferon-alpha / Q000494:pharmacology; D053139:Oseltamivir / Q000494:pharmacology; D012254:Ribavirin / Q000494:pharmacology; D013329:Structure-Activity Relationship
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D053139:Oseltamivir; D012254:Ribavirin